Synaptic dysfunction in synucleinopathies

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 8, 2013, Pages 1094-1100

  Anichtchik, Oleg ^a,b   Calo, Laura ^a   Spillantini, Maria Grazia ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Alzheimer's disease; Animal models; Central nervous system; Dementia; Lewy body; Neurodegenerative disorders; Synaptic dysfunction; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE RECEPTOR; NEUROTRANSMITTER; SNARE PROTEIN; SYNAPTOPHYSIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

ALZHEIMER DISEASE; ARTICLE; CYTOLOGY; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; SYNAPSE; SYNAPTIC DYSFUNCTION; SYNAPTIC TRANSMISSION; SYNUCLEINOPATHY; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; SYNAPSES;

EID: 84891718398     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Postuma, R.B.; Aarsland, D.; Barone, P.; Burn, D.J.; Hawkes, C.H.; Oertel, W.; Ziemssen, T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov. Disord., 2012, 27 (5), 617-626.
2. Corti, O.; Lesage, S.; Brice, A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev., 2011, 91 (4), 1161-1218.
3. Polymeropoulos, M. H; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276 (5321), 2045-2047.
4. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302 (5646), 841.
5. Michell, A.W.; Barker, R.A.; Raha, S.K.; Raha-Chowdhury, R. A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. J. Neurol. Neurosurg. Psychiatry, 2005, 76 (4), 596-597.
6. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J.T.; Schöls, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 1998, 18 (2), 106-108.
7. Chartier-Harlin, M.C.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M.; Waucquier, N.; Defebvre, L.; Amouyel, P.; Farrer, M.; Destée, A. alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 2004, 364 (9440), 1167-1169.
8. Braak, H.; Del Tredici, K.; Rub, U.; De Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24 (2), 197-211.
9. Perry, R.H.; Irving, D.; Blessed, G.; Fairbairn, A.; Perry, E.K. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J. Neurol. Sci., 1990, 95 (2), 119-139.
10. McKeith, I.G.; Dickson, D.W.; Lowe, J.; Emre, M.; O'Brien, J.T.; Feldman, H.; Cummings, J.; Duda, J.E.; Lippa, C.; Perry, E.K.; Aarsland, D.; Arai, H.; Ballard, C.G.; Boeve, B.; Burn, D.J.; Costa, D.; Del Ser, T.; Dubois, B.; Galasko, D.; Gauthier, S.; Goetz, C.G.; Gomez-Tortosa, E.; Halliday, G.; Hansen, L.A.; Hardy, J.; Iwatsubo, T.; Kalaria, R.N.; Kaufer, D.; Kenny, R.A.; Korczyn, A.; Kosaka, K.; Lee, V.M.; Lees, A.; Litvan, I.; Londos, E.; Lopez, O.L.; Minoshima, S.; Mizuno, Y.; Molina, J.A.; Mukaetova-Ladinska, E.B.; Pasquier, F.; Perry, R.H.; Schulz, J.B.; Trojanowski, J.Q.; Yamada, M. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 2005, 65 (12), 1863-1872.
11. Buracchio, T.; Arvanitakis, Z.; Gorbien, M. Dementia with Lewy bodies: current concepts. Dement. Geriatr. Cogn. Disord., 2005, 20 (5), 306-320.
12. Zarranz, J.J.; Alegre, J.; Gomez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Muñoz, D.G.; de Yebenes, J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 2004, 55 (2), 164-173.
13. Hansen, L.A.; Masliah, E.; Galasko, D.; Terry, R.D. Plaque-only Alzheimer disease is usually the lewy body variant, and vice versa. J. Neuropathol. Exp. Neurol., 1993, 52 (6), 648-654.
14. Papp, M.I.; Lantos, P.L. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain, 1994, 117 (Pt 2), 235-243.
15. Ahmed, Z.; Asi, Y.T.; Sailer, A.; Lees, A.J.; Houlden, H.; Revesz, T.; Holton, J.L. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol., 2012, 38 (1), 4-24.
16. Miller, D.W.; Johnson, J.M.; Solano, S.M.; Hollingsworth, Z.R.; Standaert, D.G.; Young, A.B. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural Transm., 2005, 112 (12), 1613-1624.
17. Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci., 1988, 8 (8), 2804-2815.
18. Davidson, W.S.; Jonas, A.; Clayton, D.F.; George, J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 1998, 273 (16), 9443-9449.
19. Chandra, S.; Chen, X.; Rizo, J.; Jahn, R.; Sudhof, T.C. A broken alpha-helix in folded alpha-Synuclein. J. Biol. Chem., 2003, 278 (17), 15313-15318.
20. Kingsbury, A.E.; Daniel, S.E.; Sangha, H.; Eisen, S.; Lees, A.J.; Foster, O.J. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov. Disord., 2004, 19 (2), 162-170.
21. Petersen, K.; Olesen, O.F.; Mikkelsen, J.D. Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. Neuroscience, 1999, 91 (2), 651-659.
22. McLean, J.R.; Hallett, P.J.; Cooper, O.; Stanley, M.; Isacson, O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell Neurosci., 2012, 49 (2), 230-239.
23. Wirdefeldt, K.; Bogdanovic, N.; Westerberg, L.; Payami, H.; Schalling, M.; Murdoch, G. Expression of alpha-synuclein in the human brain: relation to Lewy body disease. Brain Res. Mol. Brain Res., 2001, 92 (1-2), 58-65.
24. Quinn, J.G.; Coulson, D.T.; Brockbank, S.; Beyer, N.; Ravid, R.; Hellemans, J.; Irvine, G.B.; Johnston, J.A. alpha-Synuclein mRNA and soluble alpha-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. Brain Res., 2012, 1459, 71-80.
25. Conway, K.A.; Harper, J.D.; Lansbury, P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 1998, 4 (11), 1318-1320.
26. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T., Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 1996, 35 (43), 13709-13715.
27. Bartels, T.; Choi, J.G.; Selkoe, D.J. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 2011, 477 (7362), 107-110.
28. Wang, W.; Perovic, I.; Chittuluru, J.; Kaganovich, A.; Nguyen, L.T.; Liao, J.; Auclair, J.R.; Johnson, D.; Landeru, A.; Simorellis, A.K.; Ju, S.; Cookson, M.R.; Asturias, F.J.; Agar, J.N.; Webb, B.N.; Kang, C.; Ringe, D.; Petsko, G.A.; Pochapsky, T.C.; Hoang, Q.Q. A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA, 2011, 108 (43), 17797-17802.
29. Fauvet, B.; Mbefo, M.K.; Fares, M.B.; Desobry, C.; Michael, S.; Ardah, M.T.; Tsika, E.; Coune, P.; Prudent, M.; Lion, N.; Eliezer, D.; Moore, D.J.; Schneider, B.; Aebischer, P.; El-Agnaf, O.M.; Masliah, E.; Lashuel, H.A. Alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem., 2012, 287 (19), 15345-15364.
30. Spillantini, M.G. Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinson. Relat. Disord., 1999, 5 (4), 157-162.
31. Lue, L.F.; Walker, D.G.; Adler, C.H.; Shill, H.; Tran, H.; Akiyama, H.; Sue, L.I.; Caviness, J.; Sabbagh, M.N.; Beach, T.G. Biochemical Increase in Phosphorylated Alpha-Synuclein Precedes Histopathology of Lewy-Type Synucleinopathies. Brain Pathol., 2012, 22 (6), 745-756.
32. Inglis, K.J.; Chereau, D.; Brigham, E.F.; Chiou, S.S.; Schobel, S.; Frigon, N.L.; Yu, M.; Caccavello, R.J.; Nelson, S.; Motter, R.; Wright, S.; Chian, D.; Santiago, P.; Soriano, F.; Ramos, C.; Powell, K.; Goldstein, J.M.; Babcock, M.; Yednock, T.; Bard, F.; Basi, G.S.; Sham, H.; Chilcote, T.J.; McConlogue, L.; Griswold-Prenner, I.; Anderson, J.P. Polo-like kinase 2 (PLK2) phosphorylates alphasynuclein at serine 129 in central nervous system. J. Biol. Chem., 2009, 284 (5), 2598-2602.
33. Okochi, M.; Walter, J.; Koyama, A.; Nakajo, S.; Baba, M.; Iwatsubo, T.; Meijer, L.; Kahle, P.J.; Haass, C. Constitutive phosphorylation of the Parkinson's disease associated alphasynuclein. J. Biol. Chem., 2000, 275 (1), 390-397.
34. Pronin, A.N.; Morris, A.J.; Surguchov, A.; Benovic, J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem., 2000, 275 (34), 26515-26522.
35. Qing, H.; Wong, W.; McGeer, E.G.; Mcgeer, P.L. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun., 2009, 387 (1), 149-152.
36. Muntane, G.; Ferrer, I.; Martinez-Vicente, M. Alpha-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience, 2012, 200, 106-119.
37. Hirai, Y.; Fujita, S.C.; Iwatsubo, T.; Hasegawa, M. Phosphorylated alpha-synuclein in normal mouse brain. FEBS Lett., 2004, 572 (1-3), 227-232.
38. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol., 2002, 4 (2), 160-164.
39. Smith, W.W.; Margolis, R.L.; Li, X.; Troncoso, J.C.; Lee, M.K.; Dawson, V.L.; Dawson, T.M.; Iwatsubo, T.; Ross, C.A. Alphasynuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci., 2005, 25 (23), 5544-5552.
40. Paleologou, K.E.; Schmid, A.W.; Rospigliosi, C.C.; Kim, H.Y.; Lamberto, G.R.; Fredenburg, R.A.; Lansbury, P.T., Jr.; Fernandez, C.O.; Eliezer, D.; Zweckstetter, M.; Lashuel, H.A. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem., 2008, 283 (24), 16895-16905.
41. Paleologou, K.E.; Oueslati, A.; Shakked, G.; Rospigliosi, C.C.; Kim, H.Y.; Lamberto, G.R.; Fernandez, C.O.; Schmid, A.; Chegini, F.; Gai, W.P.; Chiappe, D.; Moniatte, M.; Schneider, B.L.; Aebischer, P.; Eliezer, D.; Zweckstetter, M.; Masliah, E.; Lashuel, H.A. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synucleinmembrane interactions. J. Neurosci., 2010, 30 (9), 3184-3198.
42. Webb, J.L.; Ravikumar, B.; Atkins, J.; Skepper, J.N.; Rubinsztein, D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem., 2003, 278 (27), 25009-25013.
43. Tofaris, G.K.; Layfield, R.; Spillantini, M.G. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett., 2001, 509 (1), 22-26.
44. Cuervo, A.M.; Stefanis, L.; Fredenburg, R.; Lansbury, P.T.; Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science, 2004, 305 (5688), 1292-1295.
45. Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L. Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem., 2008, 283 (35), 23542-23556.
46. Tofaris, G.K.; Razzaq, A.; Ghetti, B.; Lilley, K.S.; Spillantini, M.G. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem., 2003, 278 (45), 44405-44411.
47. Wills, J.; Jones, J.; Haggerty, T.; Duka, V.; Joyce, J.N.; Sidhu, A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp. Neurol., 2010, 225 (1), 210-218.
48. Martinez-Vicente, M.; Talloczy, Z.; Kaushik, S.; Massey, A.C.; Mazzulli, J.; Mosharov, E.V.; Hodara, R.; Fredenburg, R.; Wu, D.C.; Follenzi, A.; Dauer, W.; Przedborski, S.; Ischiropoulos, H.; Lansbury, P.T.; Sulzer, D.; Cuervo, A.M. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest., 2008, 118 (2), 777-788.
49. Sudhof, T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci., 2004, 27, 509-547.
50. Sudhof, T.C.; Rizo, J. Synaptic vesicle exocytosis. Cold Spring Harb. Perspect. Biol., 2011, 3 (12), a005637.
51. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Flanagan, L.; de Silva, H.A.; Kittel, A.; Saitoh, T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 1995, 14 (2), 467-475.
52. Liu-Yesucevitz, L.; Bassell, G.J.; Gitler, A.D.; Hart, A.C.; Klann, E.; Richter, J.D.; Warren, S.T.; Wolozin, B. Local RNA translation at the synapse and in disease. J. Neurosci., 2011, 31 (45), 16086-16093.
53. Jensen, P.H.; Li, J.Y.; Dahlstrom, A.; Dotti, C.G. Axonal transport of synucleins is mediated by all rate components. Eur. J. Neurosci., 1999, 11 (10), 3369-3376.
54. Li, W.; Hoffman, P.N.; Stirling, W.; Price, D.L.; Lee, M.K. Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J. Neurochem., 2004, 88 (2), 401-410.
55. Saha, A.R.; Hill, J.; Utton, M.A.; Asuni, A.A.; Ackerley, S.; Grierson, A.J.; Miller, C.C.; Davies, A.M.; Buchman, V.L.; Anderton, B.H.; Hanger, D.P. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci., 2004, 117 (Pt 7), 1017-1024.
56. Volles, M.J.; Lee, S.J.; Rochet, J.C.; Shtilerman, M.D.; Ding, T.T.; Kessler, J.C.; Lansbury, P.T., Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 2001, 40 (26), 7812-7819.
57. Volles, M.J.; Lansbury, P.T., Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's diseaselinked mutations and occurs by a pore-like mechanism. Biochemistry, 2002, 41 (14), 4595-4602.
58. Zakharov, S.D.; Hulleman, J.D.; Dutseva, E.A.; Antonenko, Y.N.; Rochet, J.C.; Cramer, W.A. Helical alpha-synuclein forms highly conductive ion channels. Biochemistry, 2007, 46 (50), 14369-14379.
59. Kahle, P.J.; Neumann, M.; Ozmen, L.; Muller, V.; Jacobsen, H.; Schindzielorz, A.; Okochi, M.; Leimer, U.; van Der Putten, H.; Probst, A.; Kremmer, E.; Kretzschmar, H.A.; Haass, C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci., 2000, 20 (17), 6365-6373.
60. Zhang, L.; Zhang, C.; Zhu, Y.; Cai, Q.; Chan, P.; Ueda, K.; Yu, S.; Yang, H. Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res., 2008, 1244, 40-52.
61. Fortin, D.L.; Nemani, V.M.; Voglmaier, S.M.; Anthony, M.D.; Ryan, T.A.; Edwards, R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci., 2005, 25 (47), 10913-10921.
62. Abeliovich, A.; Schmitz, Y.; Farinas, I.; Choi-Lundberg, D.; Ho, W.H.; Castillo, P.E.; Shinsky, N.; Verdugo, J.M.; Armanini, M.; Ryan, A.; Hynes, M.; Phillips, H.; Sulzer, D.; Rosenthal, A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 2000, 25 (1), 239-252.
63. Cabin, D.E.; Shimazu, K.; Murphy, D.; Cole, N.B.; Gottschalk, W.; McIlwain, K.L.; Orrison, B.; Chen, A.; Ellis, C.E.; Paylor, R.; Lu, B.; Nussbaum, R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci., 2002, 22 (20), 8797-8807.
64. Nemani, V.M.; Lu, W.; Berge, V.; Nakamura, K.; Onoa, B.; Lee, M.K.; Chaudhry, F.A.; Nicoll, R.A.; Edwards, R.H. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 2010, 65 (1), 66-79.
65. Lundblad, M.; Decressac, M.; Mattsson, B.; Björklund, A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. USA, 2012, 109 (9), 3213-3219.
66. Chung, C.Y.; Koprich, J.B.; Siddiqi, H.; Isacson, O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J. Neurosci., 2009, 29 (11), 3365-3373.
67. Gaugler, M.N.; Genc, O.; Bobela, W.; Mohanna, S.; Ardah, M.T.; El-Agnaf, O.M.; Cantoni, M.; Bensadoun, J.C.; Schneggenburger, R.; Knott, G.W.; Aebischer, P.; Schneider, B.L. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol., 2012, 123 (5), 653-669.
68. Alim, M.A.; Ma, Q.L.; Takeda, K.; Aizawa, T.; Matsubara, M.; Nakamura, M.; Asada, A.; Saito, T.; Kaji, H.; Yoshii, M.; Hisanaga, S.; Uéda, K. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J. Alzheimers Dis., 2004, 6 (4), 435-442.
69. Esposito, A.; Dohm, C.P.; Kermer, P.; Bahr, M.; Wouters, F.S. Alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol. Dis., 2007, 26 (3), 521-531.
70. Bellani, S.; Sousa, V.L.; Ronzitti, G.; Valtorta, F.; Meldolesi, J.; Chieregatti, E. The regulation of synaptic function by alphasynuclein. Commun. Integr. Biol., 2010, 3 (2), 106-109.
71. Sousa, V.L.; Bellani, S.; Giannandrea, M.; Yousuf, M.; Valtorta, F.; Meldolesi, J.; Chieregatti, E. {alpha}-synuclein and its A30P mutant affect actin cytoskeletal structure and dynamics. Mol. Biol. Cell, 2009, 20 (16), 3725-3739.
72. Burre, J.; Sharma, M.; Tsetsenis, T.; Buchman, V.; Etherton, M.R.; Sudhof, T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 2010, 329 (5999), 1663-1667.
73. Chandra, S.; Gallardo, G.; Fernandez-Chacon, R.; Schluter, O.M.; Sudhof, T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 2005, 123 (3), 383-396.
74. Garcia-Reitbock, P.; Anichtchik, O.; Bellucci, A.; Iovino, M.; Ballini, C.; Fineberg, E.; Ghetti, B.; Della Corte, L.; Spano, P.; Tofaris, G.K.; Goedert, M.; Spillantini, M.G. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain, 2010, 133 (Pt 7), 2032-2044.
75. Bellucci, A.; Navarria, L.; Falarti, E.; Zaltieri, M.; Bono, F.; Collo, G.; Spillantini, M.G.; Missale, C.; Spano, P.F. Redistribution of DAT/-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS One, 2011, 6 (12), e27959.
76. Costa, C.; Sgobio, C.; Siliquini, S.; Tozzi, A.; Tantucci, M.; Ghiglieri, V.; Di Filippo, M.; Pendolino, V.; de Iure, A.; Marti, M.; Morari, M.; Spillantini, M.G.; Latagliata, E.C.; Pascucci, T.; Puglisi-Allegra, S.; Gardoni, F.; Di Luca, M.; Picconi, B.; Calabresi, P. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. Brain, 2012, 135 (Pt 6), 1884-1899.
77. Sharma, M.; Burre, J.; Sudhof, T.C. CSPalpha promotes SNAREcomplex assembly by chaperoning SNAP-25 during synaptic activity. Nat. Cell Biol., 2011, 13 (2), 182.
78. Fearnley, J.M.; Lees, A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 1991, 114 (Pt 5), 2283-2301.
79. Ma, S.Y.; Roytta, M.; Rinne, J.O.; Collan, Y.; Rinne, U.K. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J. Neurol. Sci., 1997, 151 (1), 83-87.
80. Greffard, S.; Verny, M.; Bonnet, A.M.; Beinis, J.Y.; Gallinari, C.; Meaume, S.; Piette, F.; Hauw, J.J.; Duyckaerts, C. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol., 2006, 63 (4), 584-588.
81. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Jellinger, K.; Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 1973, 20 (4), 415-455.
82. Hilker, R.; Schweitzer, K.; Coburger, S.; Ghaemi, M.; Weisenbach, S.; Jacobs, A.H.; Rudolf, J.; Herholz, K.; Heiss, W.D. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol., 2005 62 (3), 378-382.
83. Ouchi, Y.; Yoshikawa, E.; Sekine, Y.; Futatsubashi, M.; Kanno, T.; Ogusu, T.; Torizuka, T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol., 2005, 57 (2), 168-175.
84. Heiss, W. D; Hilker, R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur. J. Neurol., 2004, 11 (1), 5-12.
85. Nikolaus, S.; Antke, C.; Kley, K.; Poeppel, T.D.; Hautzel, H.; Schmidt, D.; Müller, H.W. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev. Neurosci., 2007, 18 (6), 439-472.
86. Anglade, P.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration, 1996, 5 (2), 121-128.
87. Piggott, M.A.; Ballard, C.G.; Rowan, E.; Holmes, C.; McKeith, I.G.; Jaros, E.; Perry, R.H.; Perry, E.K. Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. Synapse, 2007, 61 (11), 903-911.
88. Hansen, L.A.; Daniel, S.E.; Wilcock, G.K.; Love, S. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. J. Neurol. Neurosurg. Psychiatry, 1998, 64 (5), 653-656.
89. Mukaetova-Ladinska, E.B.; Xuereb, J.H.; Garcia-Sierra, F.; Hurt, J.; Gertz, H.J.; Hills, R.; Brayne, C.; Huppert, F.A.; Paykel, E.S.; McGee, M.A.; Jakes, R.; Honer, W.G.; Harrington, C.R.; Wischik, C.M. Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alphasynuclein in medial temporal lobe. Sci. World J., 2009, 9, 1463-1475.
90. Kramer, M.L.; Schulz-Schaeffer, W.J. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci., 2007, 27 (6), 1405-1410.
91. Campbell, B.C.; Li, Q.X.; Culvenor, J.G.; Jakala, P.; Cappai, R.; Beyreuther, K.; Masters, C.L.; McLean, C.A. Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol. Dis., 2000, 7 (3), 192-200.
92. Larson, M.E.; Sherman, M.A.; Greimel, S.; Kuskowski, M.; Schneider, J.A.; Bennett, D.A.; Lesné, S.E. Soluble alpha-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology. J. Neurosci., 2012, 32 (30), 10253-10266.
93. Nakamura, S.; Kawamoto, Y.; Nakano, S.; Akiguchi, I. Expression of the endocytosis regulatory proteins Rab5 and Rabaptin-5 in glial cytoplasmic inclusions from brains with multiple system atrophy. Clin. Neuropathol., 2000, 19 (2), 51-56.
94. Dalfo, E.; Ferrer, I. Alpha-synuclein binding to rab3a in multiple system atrophy. Neurosci. Lett., 2005, 380 (1-2), 170-175.
95. Pfeffer, S.R. Rab GTPases: master regulators of membrane trafficking. Curr. Opin. Cell Biol., 1994, 6 (522-526).
96. Scherfler, C.; Khan, N.L.; Pavese, N.; Eunson, L.; Graham, E.; Lees, A.J.; Quinn, N.P.; Wood, N.W.; Brooks, D.J.; Piccini, P.P. Striatal and cortical pre-and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain, 2004, 127 (Pt 6), 1332-1342.
97. Vincent, A.; Briggs, L.; Chatwin, G.F.; Emery, E.; Tomlins, R.; Oswald, M.; Middleton, C.A.; Evans, G.J.; Sweeney, S.T.; Elliott, C.J. Parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress. Hum. Mol. Genet., 2012, 21 (8), 1760-1769.
98. Bloch, A.; Probst, A.; Bissig, H.; Adams, H.; Tolnay, M. Alphasynuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol., 2006, 32 (3), 284-295.
99. Orimo, S.; Takahashi, A.; Uchihara, T.; Mori, F.; Kakita, A.; Wakabayashi, K.; Takahashi, H. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol., 2007, 17 (1), 24-30.